more

Galapagos (GLPG)

(Delayed Data from NSDQ)

$24.81 USD

-0.67 (-2.63%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $24.81 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Best Momentum Stocks to Buy for December 13th

by Zacks Equity Research Published on December 13,2023

GLPG, BBVA and TW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 13, 2023.

finance

New Strong Buy Stocks for December 13th

by Zacks Equity Research Published on December 13,2023

TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.

Dynavax Technologies (DVAX) Soars 5.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research Published on June 13,2023

Dynavax Technologies (DVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023

by Zacks Equity Research Published on December 28,2022

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect?

by Zacks Equity Research Published on December 16,2022

The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

GLPGNegative Net Change

Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround

by Zacks Equity Research Published on December 08,2022

Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

GLPGNegative Net Change

Strength Seen in Galapagos NV (GLPG): Can Its 8% Jump Turn into More Strength?

by Zacks Equity Research Published on September 13,2022

Galapagos NV (GLPG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Are Medical Stocks Lagging Galapagos (GLPG) This Year?

by Zacks Equity Research Published on June 29,2022

Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.

Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA

by Zacks Equity Research Published on June 16,2022

The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.

biotechs

Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High?

by Zacks Equity Research Published on June 09,2022

The consensus price target hints at a 28.3% upside potential for Galapagos NV (GLPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

GLPGNegative Net Change

Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on June 02,2022

Here is how Galapagos NV (GLPG) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on May 16,2022

Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs

by Zacks Equity Research Published on May 11,2022

Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.

Has Galapagos (GLPG) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on April 28,2022

Here is how Galapagos NV (GLPG) and MedAvail Holdings, Inc. (MDVL) have performed compared to their sector so far this year.

GLPGNegative Net Change

Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength?

by Zacks Equity Research Published on April 04,2022

Galapagos NV (GLPG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study

by Zacks Equity Research Published on October 05,2021

Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

by Zacks Equity Research Published on July 15,2021

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

biotechs

Gilead (GILD) & Galapagos Discontinue Development of IPF Drug

by Zacks Equity Research Published on February 11,2021

Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.